Bright Minds Biosciences (DRUG) Price & Analysis

Compare

244 Followers

DRUG Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.04 - $79.02

Previous Close$40.4

Volume34.65K

Average Volume (3M)94.75K

Market Cap

C$354.39M

Enterprise Value$204.27M

Total Cash (Recent Filing)C$51.39M

Total Debt (Recent Filing)C$141.03K

Price to Earnings (P/E)―

Beta3.91

Next Earnings

Dec 18, 2025

EPS Estimate

-0.56

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding7,084,639

10 Day Avg. Volume81,734

30 Day Avg. Volume94,745

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

C$78.90

Price Target Upside28.48% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentPositive data from the Phase 2 readout could establish a clear path into pivotal development and position BMB-101 as a best-in-class therapy for rare, drug-resistant epilepsies.

Drug EfficacyThe drug's ability to activate 5-HT2C without also stimulating the beta-arrestin pathway has the potential to avoid the tolerance seen with earlier 5-HT2C drugs.

Market OpportunityAbsence seizures represent a blockbuster opportunity with about 75,000 patients in the US having forms of epilepsy where absence seizures predominate.

Bears Say

Development RiskThe Phase 2 BREAKTHROUGH trial evaluating BMB-101 in absence epilepsy and developmental and epileptic encephalopathies remains on track to deliver top-line data, which could de-risk the program and pave the way for advancement to Phase 3.

Market CompetitionThe bar for seizure drugs is a 50% reduction in half the patients, and epilepsy patients and their caregivers are highly compliant, which is favorable for drug development in this area.

Bright Minds Biosciences News

Psychedelic: Cybin completes enrollment in CYB004 Phase 2 study

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

29d ago

CYBN

DRUG

Bright Minds Biosciences’ Promising Pipeline and Strategic Expansion Justify Buy Rating

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, retaining the price target...

25d ago

DRUG

Bright Minds initiated with a Buy at BTIG

BTIG initiated coverage of Bright Minds (DRUG) with a Buy rating and $72 price target The company is...

1M ago

DRUG

Bright Minds Biosciences Launches $100 Million At-The-Market Offering

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an update. Bright Minds Biosciences announced an at-the-market equity offering...

1M ago

DRUG

Psychedelic: Bright Minds reports preclinical BMB-201 results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

1M ago

CMPS

CYBN

Bright Minds says BMB-201 outperforms sumatriptan in preclinical model

Bright Minds (DRUG) Biosciences announced preclinical results for its investigational compound BMB-201, in a validated isosorbide dinitrate rat...

1M ago

DRUG

Bright Minds Biosciences: Advancing Breakthrough Epilepsy Treatment with BMB-101 and Strong Financial Position

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences, retaining the price target...

2M ago

DRUG

Bright Minds Biosciences Reports Q3 2025 Financial Results

Bright Minds Biosciences ( ($TSE:DRUG) ) has shared an announcement. Bright Minds Biosciences Inc. has released its Condensed...

2M ago

DRUG

Psychedelic: atai Life Sciences, Cybin report earnings results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

2M ago

ATAI

CYBN

Psychedelic: atai Life Sciences, Beckley Psytech report BPL-003 study results

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

3M ago

ATAI

CMND

Bright Minds assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Bright Minds (DRUG) with an Overweight rating and no price target Bright Minds’...

3M ago

DRUG

Bright Minds Biosciences to Present at 2025 Jefferies Global Healthcare Conference

Bright Minds Biosciences ( ($TSE:DRUG) ) has provided an announcement. Bright Minds Biosciences announced that its CEO and...

4M ago

DRUG

Bright Minds Biosciences’ BMB-101: A Promising Breakthrough in Treatment-Resistant Epilepsy

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Bright Minds Biosciences...

5M ago

DRUG

Bright Minds Biosciences: Buy Rating Issued on Promising Potential of BMB-101 for Absence Seizures

TD Cowen analyst Joseph Thome has maintained their bullish stance on DRUG stock, giving a Buy rating on...

5M ago

DRUG

DRUG FAQ

What was Bright Minds Biosciences’s price range in the past 12 months?

Bright Minds Biosciences lowest stock price was $1.04 and its highest was $79.02 in the past 12 months.

What is Bright Minds Biosciences’s market cap?

Bright Minds Biosciences’s market cap is C$354.39M.

When is Bright Minds Biosciences’s upcoming earnings report date?

Bright Minds Biosciences’s upcoming earnings report date is Dec 18, 2025 which is in 69 days.

How were Bright Minds Biosciences’s earnings last quarter?

Bright Minds Biosciences released its earnings results on Aug 14, 2025. The company reported -$0.528 earnings per share for the quarter, beating the consensus estimate of -$0.567 by $0.039.

Is Bright Minds Biosciences overvalued?

According to Wall Street analysts Bright Minds Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Bright Minds Biosciences pay dividends?

Bright Minds Biosciences does not currently pay dividends.

What is Bright Minds Biosciences’s EPS estimate?

Bright Minds Biosciences’s EPS estimate is -0.56.

How many shares outstanding does Bright Minds Biosciences have?

Bright Minds Biosciences has 7,084,639 shares outstanding.

What happened to Bright Minds Biosciences’s price movement after its last earnings report?

Bright Minds Biosciences reported an EPS of -$0.528 in its last earnings report, beating expectations of -$0.567. Following the earnings report the stock price went up 4.92%.

Which hedge fund is a major shareholder of Bright Minds Biosciences?

Currently, no hedge funds are holding shares in DRUG

Bright Minds Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-30.79%

Trailing 12-Months

Asset Growth

736.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Bright Minds Biosciences

Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

Bright Minds Biosciences (DRUG) Earnings & Revenues

Historic Earnings Reports

DRUG Stock 12 Month Forecast

Average Price Target

$78.90

▲(28.48% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","43":"$43","86":"$86","21.5":"$21.5","64.5":"$64.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":85.4361507741453,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$85.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.89985282,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$78.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":72.36944536162896,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$72.37</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,21.5,43,64.5,86],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.95,60.06431929031887,62.17863858063774,64.29295787095661,66.40727716127549,68.52159645159435,70.63591574191322,72.75023503223208,74.86455432255096,76.97887361286982,79.0931929031887,81.20751219350757,83.32183148382643,{"y":85.4361507741453,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.95,59.56152714,61.17305428,62.78458142,64.39610856,66.00763570000001,67.61916284,69.23068998000001,70.84221712,72.45374426000001,74.0652714,75.67679854000001,77.28832568000001,{"y":78.89985282,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.95,59.05918810474069,60.16837620948138,61.27756431422207,62.38675241896276,63.495940523703446,64.60512862844413,65.71431673318483,66.82350483792551,67.93269294266621,69.04188104740689,70.15106915214758,71.26025725688827,{"y":72.36944536162896,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.1,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":48.18,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.02,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.24,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.11,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.58,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >